The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to treat transthyretin amyloid ...

FDA approved Alnylam's Amvuttra for ATTR-CM, making it the first treatment cleared for both ATTR-CM and hATTR-PN in adults. In trials, Amvuttra cut mortality risk by 36% through 42 months and ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals drug Amvuttra to treat transthyretin amyloid ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...